Background:
Despite effective oral PrEP, barriers to uptake and adherence persist, including stigma, substance use (SU), housing/food insecurity, and mental health issues. Long-acting cabotegravir (CAB) PrEP is highly efficacious and may address barriers for patients with adherence challenges, but uptake has been low and real-world data is lacking.
Methods:
We describe a CAB demonstration project at Ward 86, an urban safety-net clinic in San Francisco serving vulnerable patients with high rates of homelessness, mental illness, and SU living with or at risk for HIV. Patients were initiated on CAB via a structured process of provider referral and multidisciplinary review and monitored for on-time injections. Patients were offered low-barrier, multidisciplinary care with rapid PrEP initiation. We report CAB PrEP program evaluation data from chart extraction and PrEP tracking logs for patients initiated on CAB between 3/1/2022-6/1/2023 and followed through 9/1/2023. On-time injections were defined as given 28±7 days for initiation/re-initiation doses or 56±7 days for maintenance doses.
Results:
We initiated 30 participants on CAB PrEP: 70% cisgender men, 13% cisgender women, 7% transgender women, 10% nonbinary people. Median age was 39 years (range 21-63); 10% of participants were Black, 30% Hispanic, 7% Asian/Pacific Islander, 3% multi-racial. Of the 30, 20% were homeless; 23% were unstably housed. All participants had public insurance (93%) or were uninsured (7%). Active SU disorder was documented in 67%; 53% had at least 1 serious mental illness. We administered 184 injections during the study period, with a median of 6 injections/person (range 1-10). Median time from CAB referral to first injection was 14 days (range 0-111). The median duration of follow-up was 271 days (IQR 87-469). All patients had direct-to-inject CAB; 50% were not on oral PrEP at CAB initiation. Of 157 scheduled follow-up injections, 86% were on time, 4% early, 8% late, and 2% missed/not done. Of late or missed/not done injections, 47% were ≥1 month late, of which 43% were covered by oral PrEP bridging. CAB was discontinued by 3 participants for risk change (1), loss-to-follow-up (1), and transfer of care (1). All remain HIV-negative.
Conclusions:
This demonstration project shows that a rapid start CAB PrEP program serving patients with numerous psychosocial stressors is feasible and has high retention. Delivery of CAB via a low-barrier, comprehensive care model may expand uptake to high-risk, adherence-challenged populations.